The FDA has approved Xenleta (lefamulin; Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Multidrug-resistant Candida auris is an urgent antimicrobial resistance threat and the key method of prevention is strict adherence to infection control measures.
However, the results of a study titled Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis investigated whether a partial oral regimen may lead to equivalent outcomes.
The use of levofloxacin as prophylaxis for the prevention of neutropenic fever and bloodstream infections was associated with less disruption of the gut microbiome in patients with hematologic malignancy.
The FDA has approved pretomanid tablets in combination with bedaquiline and linezolid for the treatment of adults with pulmonary XDR, treatment-intolerant or nonresponsive MDR tuberculosis.
Investigators evaluated changes in the microbiology of osteomyelitis over a 10-year period, including infection with multidrug-resistant bacteria and susceptibility of antimicrobial regimens.
Investigators performed a comprehensive review on the prevalence of nonprescription antibiotic use in the United States and analyzed the factors that influence it.
The association of S aureus with food sensitization and allergy could influence interventions aimed at inducing and maintaining tolerance to food allergens in eczematous infants.
In a review update, XpertMTB/RIF was found to be sensitive and specific for diagnosing pulmonary TB and rifampicin resistance which is consistent with the last review completed in 2014.
